Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.23−0.20 (-0.19%)
Close on Nov 18, 2026Market cap $60.65BP/E 60.5Yield –
Edwards Lifesciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Edwards Lifesciences's free cash flow for the twelve months ending Jun 30, 2026 was $1.43B, up 143.9% year over year. For fiscal 2025 it was $1.34B, up 360.5% from the year before. Over ten years it grew 11.6% a year on average. The highest annual figure on record is $1.41B in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34B | +360.5% |
| FY2024 | Dec 31, 2024 | $289.90M | -54.9% |
| FY2023 | Dec 31, 2023 | $642.80M | -34.0% |
| FY2022 | Dec 31, 2022 | $973.60M | -30.8% |
| FY2021 | Dec 31, 2021 | $1.41B | +117.3% |
| FY2020 | Dec 31, 2020 | $647.30M | -30.3% |
| FY2019 | Dec 31, 2019 | $928.50M | +35.0% |
| FY2018 | Dec 31, 2018 | $688.00M | -17.4% |
| FY2017 | Dec 31, 2017 | $832.60M | +57.6% |
| FY2016 | Dec 31, 2016 | $528.30M | +18.2% |
| FY2015 | Dec 31, 2015 | $447.00M | -52.4% |
| FY2014 | Dec 31, 2014 | $939.40M | +158.3% |
| FY2013 | Dec 31, 2013 | $363.70M | +43.7% |
| FY2012 | Dec 31, 2012 | $253.10M | +9.3% |
| FY2011 | Dec 31, 2011 | $231.60M | +22.2% |
| FY2010 | Dec 31, 2010 | $189.60M | +87.2% |
| FY2009 | Dec 31, 2009 | $101.30M | -1.3% |
| FY2008 | Dec 31, 2008 | $102.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $585.00M | +142.8% |
| Q1 FY2026 | Mar 31, 2026 | -$21.10M | -109.4% |
| Q4 FY2025 | Dec 31, 2025 | $353.50M | – |
| Q3 FY2025 | Sep 30, 2025 | $516.20M | +72.1% |
| Q2 FY2025 | Jun 30, 2025 | $240.90M | -15.8% |
| Q1 FY2025 | Mar 31, 2025 | $224.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$177.30M | -467.1% |
| Q3 FY2024 | Sep 30, 2024 | $299.90M | -15.8% |
| Q2 FY2024 | Jun 30, 2024 | $286.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$118.80M | -147.0% |
| Q4 FY2023 | Dec 31, 2023 | $48.30M | -77.4% |
| Q3 FY2023 | Sep 30, 2023 | $356.20M | +42.5% |
| Q2 FY2023 | Jun 30, 2023 | -$14.30M | -104.9% |
| Q1 FY2023 | Mar 31, 2023 | $252.60M | +14.5% |
| Q4 FY2022 | Dec 31, 2022 | $213.90M | -24.6% |
| Q3 FY2022 | Sep 30, 2022 | $250.00M | -46.9% |
| Q2 FY2022 | Jun 30, 2022 | $289.10M | -36.7% |
| Q1 FY2022 | Mar 31, 2022 | $220.60M | +13.4% |
| Q4 FY2021 | Dec 31, 2021 | $283.80M | -1.0% |
| Q3 FY2021 | Sep 30, 2021 | $471.20M | +317.7% |
| Q2 FY2021 | Jun 30, 2021 | $456.80M | +271.4% |
| Q1 FY2021 | Mar 31, 2021 | $194.50M | +55.7% |
| Q4 FY2020 | Dec 31, 2020 | $286.60M | -13.5% |
| Q3 FY2020 | Sep 30, 2020 | $112.80M | -68.8% |
| Q2 FY2020 | Jun 30, 2020 | $123.00M | -55.5% |
| Q1 FY2020 | Mar 31, 2020 | $124.90M | – |
| Q4 FY2019 | Dec 31, 2019 | $331.40M | +40.8% |
| Q3 FY2019 | Sep 30, 2019 | $361.20M | +40.4% |
| Q2 FY2019 | Jun 30, 2019 | $276.60M | +216.5% |
| Q1 FY2019 | Mar 31, 2019 | -$40.70M | -137.7% |
| Q4 FY2018 | Dec 31, 2018 | $235.30M | -24.6% |
| Q3 FY2018 | Sep 30, 2018 | $257.20M | -4.2% |
| Q2 FY2018 | Jun 30, 2018 | $87.40M | -37.4% |
| Q1 FY2018 | Mar 31, 2018 | $108.10M | -3.8% |
| Q4 FY2017 | Dec 31, 2017 | $312.00M | +126.3% |
| Q3 FY2017 | Sep 30, 2017 | $268.50M | +70.2% |
| Q2 FY2017 | Jun 30, 2017 | $139.70M | – |
| Q1 FY2017 | Mar 31, 2017 | $112.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $137.90M | – |
| Q3 FY2016 | Sep 30, 2016 | $157.80M | – |
See a number that looks wrong?